KRM Ayurveda IPO: Listing Expectations, Subscription, GMP Update

KRM Ayurveda Ltd., an Ayurvedic healthcare and wellness services provider, completed its SME IPO subscription recently, with market participants watching key indicators like Grey Market Premium (GMP) and subscription trends as the issue proceeds toward listing.

📅 IPO Timeline & Key Dates

IPO Opened: 19 January 2026
IPO Closed: 23 January 2026
Allotment Date: 27 January 2026
Refund Initiation: 28 January 2026
Shares Credited to Demat: 28 January 2026
Listing Date: 29 January 2026 (on NSE SME)

📈 Issue Details and Price Band

Price Band: ₹128 to ₹135 per share
Face Value: ₹10 per share
Total Issue Size: ₹77.49 crore (book-built)
Lot Size: 1,000 shares
Retail investors typically apply for a minimum of 2,000 shares (₹2.70 lakh at the upper band).

Company at a Glance
KRM Ayurveda operates a network of six hospitals and five clinics across India, offering a mix of inpatient healthcare, outpatient services, Panchakarma therapy, wellness programs, and telemedicine consultations. The company also manufactures and sells Ayurvedic medicines and wellness products.

Subscription & Demand Trends

The IPO saw robust demand across investor categories:

Qualified Institutional Buyers (QIBs) were subscribed ~63× the offered quota.
Non-Institutional Investors (NIIs) reported ~135× subscription.
Retail investors showed healthy uptake at ~54× subscription.
Overall subscription stood around ~74× by the final day.

This strong oversubscription indicates significant investor interest, particularly from institutional and high-value segments ahead of listing.

GMP (Grey Market Premium) – Outlook Near Listing

Although the InvestorGain page currently shows no live GMP data, other market sources report that KRM Ayurveda shares were trading at a positive grey market premium ahead of listing—signaling anticipated listing gains. On reports closer to the end of subscription, GMP was noted around ₹14–₹18+ levels over the upper price band, implying expected listing prices above the issue range.

Remember, GMP is unofficial and unregulated, so it can fluctuate and may not directly reflect actual listing performance.

Market Sentiment & What Investors Are Watching

A positive GMP trend typically suggests expectations of premium listing prices relative to the IPO issue price.
Strong subscription levels across categories, especially QIB and HNI segments, indicate solid institutional appetite for the shares.
Retail investor participation, while healthy, generally lags institutional demand in SME IPOs—a pattern seen here too.

Analysts caution that GMP movements and subscription numbers should be considered alongside company fundamentals before making investment decisions, as IPO performance can vary on listing day.